-
KR-12 Design Principles and Antimicrobial Applications
2026-09-21
The reference review presents KR-12 as the smallest antibacterial fragment of human LL-37 and maps how sequence engineering, formulation, and biomaterial immobilization can tune its activity. Its practical significance lies in combining membrane-directed antibacterial effects with anti-biofilm, endotoxin-neutralizing, and immune-regulatory functions while emphasizing the limits of translating heterogeneous peptide studies into therapies.
-
HyperScribe™ Kit II for mRNA Synthesis
2026-09-21
Explore how an mRNA synthesis kit can support cap, poly(A), and T7-based workflows for inflammatory disease research. This article translates a fibroblast–LNP study into practical decisions for designing translational mRNA assays.
-
Neuromedin S (rat): Workflow and QC Guide
2026-09-20
Neuromedin S (rat), SKU B5466, provides a defined endogenous peptide agonist for controlled neuromedin U receptor and GPCR/G protein signaling workflows. This guide covers preparation, assay controls, and stability boundaries; the reagent is for research use only and should not be used for diagnostic, therapeutic, or clinical interpretation.
-
HBTU to Translational Immunoproteasome Probes
2026-09-19
HBTU can help translational researchers connect reproducible peptide bond formation with activity-based immunoproteasome probe development. This article explains the chemistry, assay implications, workflow controls, and realistic boundaries between a peptide coupling reagent, a research tool, and clinical translation.
-
HBTU for Peptide Synthesis: Mechanism and Limits
2026-09-18
HBTU, also called 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, is a peptide coupling reagent for carboxylic acid activation and peptide bond formation. This article explains its reaction logic, solid-phase peptide synthesis workflow, storage boundaries, and the limits of connecting HBTU chemistry with enzyme-responsive cancer-selective peptides.
-
Nurr1 Neurogenetic Gradients in the Rat Claustrum
2026-09-18
Fang, Wang, and Naumann mapped when Nurr1-positive neurons arise in the rat claustrum and lateral cortex, resolving regional differences that were difficult to distinguish in earlier birth-dating studies. Their combination of developmental Nurr1 expression mapping with EdU-based birth dating reveals sequential neurogenesis and previously underappreciated ventral-to-dorsal and posterior-to-anterior gradients.
-
KR-12: From Membrane Activity to Colitis Evidence
2026-09-17
KR-12 human antimicrobial peptide research spans membrane disruption, microbiota changes, and inflammation control. This evidence-led article explains how to translate KR-12 findings into better assay design without confusing antimicrobial potency with host-response effects.
-
LL-37 Fragments Against MDR Acinetobacter Biofilms
2026-09-17
The reference study evaluates LL-37 and three fragments, including KR-12, against multidrug-resistant Acinetobacter baumannii. Its main contribution is to connect rapid bactericidal activity with inhibition of adherence and established biofilms, while also showing that fragment performance varies substantially by assay and endpoint.
-
HBTU Chemistry for Peptide Probe Design
2026-09-16
Explore how HBTU enables controlled peptide bond formation and supports the synthesis of assay-ready proteasome probes. This guide connects carboxylic acid activation and racemization-resistant coupling with practical decisions in bioluminescent peptide assay development.
-
CX-5461 in Cervical Cancer: Mitotic Catastrophe
2026-09-16
The reference study shows that the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth through a DNA damage response that forces damaged cells into abnormal mitosis and mitotic catastrophe. Its enhancement of cisplatin sensitivity provides a mechanistic rationale for investigating Pol I inhibition in treatment-resistant cervical cancer models.
-
Metabolite Binding and TET2 Regulation: A Protocol Guide
2026-09-15
Zhang and colleagues present an integrated workflow that combines biochemical TET2 activity assays with saturation transfer difference NMR to distinguish metabolite binding from functional regulation. The protocol validates known TET2 activators and inhibitors while providing a practical route for discovering additional metabolic regulators, including glyoxylate.
-
Cyclo (-RGDfC) in High-Throughput Integrin Assays
2026-09-15
Cyclo (-RGDfC) combines cyclic RGD recognition with practical DMSO handling for αvβ3-focused adhesion, angiogenesis, and tumor-targeting experiments. Pairing the peptide with 96-well hydrogel printing creates a scalable route to spatially organized cancer research assays while preserving essential receptor and vehicle controls.
-
Indazole/Indole Glucagon Receptor Antagonists
2026-09-14
This 2015 Bioorganic & Medicinal Chemistry Letters study describes indazole- and indole-based glucagon receptor antagonists derived from the MK-0893 program. Structure–activity relationship analysis produced compounds with strong in vitro activity and favorable rat pharmacokinetics, while GRA 16d reduced glucagon-driven glucose excursions after oral dosing in humanized-receptor mouse models.
-
Annexin V-FITC/PI Apoptosis Assay Kit Workflow
2026-09-14
Turn phosphatidylserine externalization and membrane damage into a rapid, stage-resolved apoptosis readout. This workflow shows how to apply dual staining to sodium selenite studies, flow cytometry apoptosis detection, and mechanistic troubleshooting.
-
HEY2, Mitochondrial Respiration, and Cardiac Homeostasis
2026-09-13
The reference study identifies HEY2 as an evolutionarily conserved transcriptional brake on mitochondrial oxidative metabolism in cardiomyocytes. By integrating animal models, human cardiomyocyte-like cells, genome-wide analyses, and rescue experiments, it connects HEY2/HDAC1 repression of the PPARGC1A–ESRRA–CPT1 axis with cardiac dysfunction and doxorubicin-induced injury.